The Artera MMAI Score is produced based on the patient’s digital pathology image and clinical data.
Determine if the patient has high or low metastatic volume per CHAARTED criteria:
High Volume: ≥4 bone lesions, with ≥1 outside the spine or pelvis, or presence or visceral metastasis
Low Volume: mHSPC patients that do not meet high volume criteria
MMAI score percentile
MMAI score percentile for the patient compared to distribution among M1 STAMPEDE patients (Arms A, C, E, G, and J; n=1598), represented numerically and visually in low-volume and high-volume subgroups. Within this cohort, 43% of patients had low metastatic disease volume and 48% of patients had high metastatic disease volume.
Personalized 5-year PCSM estimate
Personalized 5-year PCSM estimate based on the patient’s MMAI score, derived from STAMPEDE patients treated with androgen deprivation therapy plus abiraterone (Arm G, n=245) or androgen deprivation therapy plus abiraterone plus enzalutamide (Arm J, n=297) using the Fine & Gray competing risk model. Predicted 5-year PCSM risks were estimated across the range of MMAI scores for high- and low-volume subgroups from the fitted model. The vertical dashed line indicates the patient’s predicted MMAI score and the corresponding 5-year PCSM risk can be read from the appropriate volume-specific curve at that value.
Your Privacy on this Website
We collect information about your visit through cookies and web beacons. You can opt out through your browser, but then you will not have access to all the functions of the website.
To learn more, read our Privacy Notice.
